D&O Ongoing Disclosure Notice – Multiple

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
27 September 2018
Date of last disclosure:
15 June 2018
Director or senior manager giving disclosure
Full name(s):
Lewis George GRADON
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Performance Shares Rights
(b) Options to acquire Ordinary Shares
(c) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest:
Number held in class before acquisition or disposal:
(a) 90,598 Performance Shares Rights
(b) 256,364 Options to acquire Ordinary Shares
(c) 579,677 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 97,064 Performance Shares Rights
(b) 326,677 Options to acquire Ordinary Shares
(c) 603,502 Ordinary Shares
Current registered holder(s):
Lewis George Gradon and Gradon Family Trust
Registered holder(s) once transfers are registered:
Lewis George Gradon and Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Five
Details of transactions requiring disclosure:

Date of transaction:
(a) 13 September 2018
(b) 13 September 2018
(c) 21 September 2018
(d) 21 September 2018
(e) 24 September 2018
Nature of transaction:
(a) Issue of 32,466 Performance Share Rights
(b) Issue of 100,313 Options to acquire Ordinary
Shares
(c) Exercise of 26,000 Performance Share Rights
and issue of 26,000 Ordinary Shares
(d) Cancellation of 30,000 Options and issue of
15,825 Ordinary Shares
(e) Sale of 18,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $0
(b) $0
(c) $396,500
(d) $241,331
(e) $271,523
Number of financial products to which the transaction related:
(a) 32,466 Performance Share Rights
(b) 100,313 Options to acquire Ordinary Shares
(c) 26,000 Performance Share Rights and 26,000
Ordinary Shares
(d) 30,000 Options to acquire Ordinary Shares and
15,825 Ordinary Shares
(e) 18,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details:
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest:
Number held in class:
Current registered holder(s):
For a derivative relevant interest:
Type of derivative:Not Applicable
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
27 September 2018
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
27 September 2018
Date of last disclosure:
21 June 2018
Director or senior manager giving disclosure
Full name(s):
Paul Nigel SHEARER
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Performance Share Rights
(b) Options to acquire Ordinary Shares
(c) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
(a) 62,153 Performance Share Rights
(b) 177,467 Options to acquire Ordinary Shares
(c) 355,018 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 58,189 Performance Share Rights
(b) 233,195 Options to acquire Ordinary Shares
(c) 377,018 Ordinary Shares
Current registered holder(s):
Paul Nigel SHEARER and Shearer Family Trust
Registered holder(s) once transfers are registered:
Paul Nigel SHEARER and Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Three
Details of transactions requiring disclosure-
Date of transaction:
(a) 13 September 2018
(b) 13 September 2018
(c) 20 September 2018

Nature of transaction:
(a) Issue of 18,036 Performance Share Rights
(b) Issue of 55,728 Options to acquire Ordinary Shares
(c) Exercise of 22,000 Performance Share Rights and issue
of 22,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $0
(b) $0
(c) $335,720
Number of financial products to which the transaction related:
(a) 18,036 Performance Share Rights
(b) 55,728 Options to acquire Ordinary Shares
(c) 22,000 Performance Share Rights and 22,000 Ordinary
Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to proceed
during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Shares in Trust under Employee Share Scheme
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
410 Shares in Trust under Employee Share Scheme
Current registered holder(s):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:27 September 2018
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
27 September 2018
Date of last disclosure:
19 June 2018
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald SOMERVELL
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Performance Shares Rights
(b) Options to acquire Ordinary Shares
(c) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
(a) 29,728 Performance Share Rights
(b) 85,241 Options to acquire Ordinary Shares
(c) 59,009 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 30,748 Performance Share Rights
(b) 116,201 Options to acquire Ordinary Shares
(c) 64,009 Ordinary Shares
Current registered holder(s):
Andrew Robert Donald SOMERVELL
Registered holder(s) once transfers are registered:
Andrew Robert Donald SOMERVELL
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Four
Details of transactions requiring disclosure-
Date of transaction:
(a) 13 September 2018
(b) 13 September 2018
(c) 13 September 2018
(d) 25 September 2018

Nature of transaction:
(a) Issue of 30,960 Options to acquire Ordinary Shares
(b) Issue of 10,020 Performance Share Rights
(c) Exercise of 9,000 Performance Share Rights and issue of
9,000 Ordinary Shares
(d) Sale of 4,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $0
(b) $0
(c) $137,250
(d) $60,720
Number of financial products to which the transaction related:
(a) 30,960 Options to acquire Ordinary Shares
(b) 10,020 Performance Share Rights
(c) 9,000 Performance Share Rights and 9,000 Ordinary
Shares
(d) 4,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Shares in Trust under Employee Share Scheme
Nature of relevant interest:
Beneficial
For that relevant interest,-
Number held in class:
410 Shares in Trust under Employee Share Scheme
Current registered holder(s):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:27 September 2018
Name and title of authorised person:Edward Timmins, Company Secretary